Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know

Bristol Myers Squibb (BMY) closed at $44.54 in the latest trading session, marking a +2.18% move from the prior day. On the other hand, the Dow registered a gain of 0.47%, and the technology-centric Nasdaq decreased by 0.16%. Prior to today's trading, shares of the biopharmaceutical company had lost 3.09% lagged the Medical sector's gain of 3.55% and the S&P 500's gain of 1.16%.The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on October 30, 2025. The company's upcoming EPS is projected at $1.55, signifying a 13.89% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.82 billion, down 0.65% from the year-ago period. For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.42 per share and a revenue of $47.34 billion, signifying shifts of +458.26% and -1.98%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.55% lower. At present, Bristol Myers Squibb boasts a Zacks Rank of #3 (Hold). From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 6.79. This denotes a discount relative to the industry average Forward P/E of 20.39. It is also worth noting that BMY currently has a PEG ratio of 2.26. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.69. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 85, this industry ranks in the top 35% of all industries, numbering over 250. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow BMY in the coming trading sessions, be sure to utilize Zacks.com. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks